Eicosanoid pathway mediator

Eicosanoid pathway mediators are a diverse class of bioactive lipids primarily derived from arachidonic acid and other polyunsaturated fatty acids through the actions of key metabolic enzymes: cyclooxygenases (COX-1, COX-2), lipoxygenases (LOX), and cytochrome P450s (CYP)[1][4][8]. Major subclasses include prostaglandins, thromboxanes, leukotrienes, and specialized pro-resolving mediators (SPMs) such as resolvins and lipoxins[2][4][3]. These mediators play crucial roles in homeostasis and pathophysiology, particularly in regulating inflammation, immune responses, blood flow, reproduction, pain, and fever[1][5][2][3]. Eicosanoid dysregulation is implicated in a wide range of diseases including disorders of inflammation (asthma, arthritis), cardiovascular disease, cancer, and neurodegeneration[1][8][6]. While many drugs target enzymes or receptors in eicosanoid pathways, "Eicosanoid pathway mediators" as a term does not specify a unique therapeutic target but rather a family and network of important signaling molecules[4][5][3]. Because "Eicosanoid pathway mediators" encompasses a family of molecules, not a specific protein or receptor, this entry is not suitable as a canonical therapeutic target record. For structured pharmacological or biological target databases, specifics such as "Cyclooxygenase-2 (COX-2)", "Leukotriene B4 receptor 1", or "Prostaglandin E2 receptor" are canonical targets that should be used instead[4][5][8].

Other names

Eicosanoidseicosanoid mediatorseicosanoid metaboliteslipid mediators of inflammation

Enzyme inhibition (e.g. COX, LOX, CYP inhibitors), Receptor antagonism (e.g. leukotriene receptor antagonists), Modulation of signaling through G protein-coupled receptors (GPCRs), Pro-resolution modulation (via SPMs)